

## Noridian Local Coverage Determination (LCD): MoIDX: NRAS Genetic Testing (L36335)

### Applicable Tests

NRAS Mutation Analysis	NeoLAB™ NRAS Mutation Analysis – Liquid Biopsy (not recommended for solid tumors)
------------------------	--

### Applicable CPT Codes

81311	81479
-------	-------

### Indications:

This is limited coverage policy for genetic testing of tumor tissue for somatic mutations in the NRAS gene (81311). Noridian will cover NRAS testing for metastatic colorectal cancer, per NCCN guidelines (Version 2.2016).

All other NRAS testing is non-covered.

### ICD-10 Codes Supporting Medical Necessity

**Group 1 Paragraph:** Although not specifically addressed in the ICD-10-CM Official Guidelines for Coding and Reporting 2016, when an encounter is for management of a complication associated with a neoplasm (NRAS testing for metastatic colon cancer), the complication (metastasis) is coded first, followed by the appropriate codes for the neoplasm.

\*Primary Diagnoses are listed in Group 1 and Secondary Diagnoses in Group 2.

### Numerical Listing:

#### Group 1 Codes:

C77.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck
C77.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes
C77.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes
C77.3	Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes
C77.4	Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes
C77.5	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes
C77.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions
C77.9	Secondary and unspecified malignant neoplasm of lymph node, unspecified
C78.00	Secondary malignant neoplasm of unspecified lung
C78.01	Secondary malignant neoplasm of right lung
C78.02	Secondary malignant neoplasm of left lung
C78.1	Secondary malignant neoplasm of mediastinum
C78.2	Secondary malignant neoplasm of pleura

C78.30	Secondary malignant neoplasm of unspecified respiratory organ
C78.39	Secondary malignant neoplasm of other respiratory organs
C78.4	Secondary malignant neoplasm of small intestine
C78.5	Secondary malignant neoplasm of large intestine and rectum
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
C78.80	Secondary malignant neoplasm of unspecified digestive organ
C78.89	Secondary malignant neoplasm of other digestive organs
C79.00	Secondary malignant neoplasm of unspecified kidney and renal pelvis
C79.01	Secondary malignant neoplasm of right kidney and renal pelvis
C79.02	Secondary malignant neoplasm of left kidney and renal pelvis

Codes listed are effective as of February 1, 2019

Noridian Healthcare Solutions, LLC is the Medicare Administrative Contractor (MAC) for Jurisdiction E and processes Medicare Part A and Part B claims for California, Nevada, Hawaii, Guam, American Samoa, and Northern Mariana Islands

Noridian Healthcare Solutions | Covers: California, Nevada, Hawaii

## Noridian Local Coverage Determination (LCD): MoIDX: NRAS Genetic Testing (L36335)

### Numerical Listing:

#### Group 1 Codes:

C79.10	Secondary malignant neoplasm of unspecified urinary organs
C79.11	Secondary malignant neoplasm of bladder
C79.19	Secondary malignant neoplasm of other urinary organs
C79.2	Secondary malignant neoplasm of skin
C79.31	Secondary malignant neoplasm of brain
C79.32	Secondary malignant neoplasm of cerebral meninges
C79.40	Secondary malignant neoplasm of unspecified part of nervous system
C79.49	Secondary malignant neoplasm of other parts of nervous system
C79.51	Secondary malignant neoplasm of bone
C79.52	Secondary malignant neoplasm of bone marrow

C79.60	Secondary malignant neoplasm of unspecified ovary
C79.61	Secondary malignant neoplasm of right ovary
C79.62	Secondary malignant neoplasm of left ovary
C79.70	Secondary malignant neoplasm of unspecified adrenal gland
C79.71	Secondary malignant neoplasm of right adrenal gland
C79.72	Secondary malignant neoplasm of left adrenal gland
C79.81	Secondary malignant neoplasm of breast
C79.82	Secondary malignant neoplasm of genital organs
C79.89	Secondary malignant neoplasm of other specified sites
C79.9	Secondary malignant neoplasm of unspecified site

### Numerical Listing:

#### Group 2 Codes:

C18.0	Malignant neoplasm of cecum
C18.1	Malignant neoplasm of appendix
C18.2	Malignant neoplasm of ascending colon
C18.3	Malignant neoplasm of hepatic flexure
C18.4	Malignant neoplasm of transverse colon
C18.5	Malignant neoplasm of splenic flexure

C18.6	Malignant neoplasm of descending colon
C18.7	Malignant neoplasm of sigmoid colon
C18.8	Malignant neoplasm of overlapping sites of colon
C18.9	Malignant neoplasm of colon, unspecified
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum

### Alpha Listing:

#### Group 1 Codes:

C77.3	Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes
C77.4	Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes
C77.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes
C77.5	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes
C77.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes
C77.9	Secondary and unspecified malignant neoplasm of lymph node, unspecified

C77.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck
C77.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions
C79.11	Secondary malignant neoplasm of bladder
C79.51	Secondary malignant neoplasm of bone
C79.52	Secondary malignant neoplasm of bone marrow
C79.31	Secondary malignant neoplasm of brain
C79.81	Secondary malignant neoplasm of breast
C79.32	Secondary malignant neoplasm of cerebral meninges

Codes listed are effective as of February 1, 2019

Noridian Healthcare Solutions, LLC is the Medicare Administrative Contractor (MAC) for Jurisdiction E and processes Medicare Part A and Part B claims for California, Nevada, Hawaii, Guam, American Samoa, and Northern Mariana Islands  
Noridian Healthcare Solutions | Covers: California, Nevada, Hawaii

## Noridian Local Coverage Determination (LCD): MoIDX: NRAS Genetic Testing (L36335)

### Alpha Listing:

#### Group 1 Codes:

C79.82	Secondary malignant neoplasm of genital organs
C78.5	Secondary malignant neoplasm of large intestine and rectum
C79.72	Secondary malignant neoplasm of left adrenal gland
C79.02	Secondary malignant neoplasm of left kidney and renal pelvis
C78.02	Secondary malignant neoplasm of left lung
C79.62	Secondary malignant neoplasm of left ovary
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
C78.1	Secondary malignant neoplasm of mediastinum
C78.89	Secondary malignant neoplasm of other digestive organs
C79.49	Secondary malignant neoplasm of other parts of nervous system
C78.39	Secondary malignant neoplasm of other respiratory organs
C79.89	Secondary malignant neoplasm of other specified sites
C79.19	Secondary malignant neoplasm of other urinary organs
C78.2	Secondary malignant neoplasm of pleura
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum
C79.71	Secondary malignant neoplasm of right adrenal gland

C79.01	Secondary malignant neoplasm of right kidney and renal pelvis
C78.01	Secondary malignant neoplasm of right lung
C79.61	Secondary malignant neoplasm of right ovary
C79.2	Secondary malignant neoplasm of skin
C78.4	Secondary malignant neoplasm of small intestine
C79.70	Secondary malignant neoplasm of unspecified adrenal gland
C78.80	Secondary malignant neoplasm of unspecified digestive organ
C79.00	Secondary malignant neoplasm of unspecified kidney and renal pelvis
C78.00	Secondary malignant neoplasm of unspecified lung
C79.60	Secondary malignant neoplasm of unspecified ovary
C79.40	Secondary malignant neoplasm of unspecified part of nervous system
C78.30	Secondary malignant neoplasm of unspecified respiratory organ
C79.9	Secondary malignant neoplasm of unspecified site
C79.10	Secondary malignant neoplasm of unspecified urinary organs

### Alpha Listing:

#### Group 2 Codes:

C18.1	Malignant neoplasm of appendix
C18.2	Malignant neoplasm of ascending colon
C18.0	Malignant neoplasm of cecum
C18.9	Malignant neoplasm of colon, unspecified
C18.6	Malignant neoplasm of descending colon
C18.3	Malignant neoplasm of hepatic flexure
C18.8	Malignant neoplasm of overlapping sites of colon
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C18.7	Malignant neoplasm of sigmoid colon

C18.5	Malignant neoplasm of splenic flexure
C18.4	Malignant neoplasm of transverse colon
C79.2	Secondary malignant neoplasm of skin
C78.4	Secondary malignant neoplasm of small intestine
C79.70	Secondary malignant neoplasm of unspecified adrenal gland
C78.80	Secondary malignant neoplasm of unspecified digestive organ
C79.00	Secondary malignant neoplasm of unspecified kidney and renal pelvis
C78.00	Secondary malignant neoplasm of unspecified lung

Codes listed are effective as of February 1, 2019

Noridian Healthcare Solutions, LLC is the Medicare Administrative Contractor (MAC) for Jurisdiction E and processes Medicare Part A and Part B claims for California, Nevada, Hawaii, Guam, American Samoa, and Northern Mariana Islands

Noridian Healthcare Solutions | Covers: California, Nevada, Hawaii



# Medicare Medical Necessity for Laboratory Testing

## Noridian Local Coverage Determination (LCD): MoIDX: NRAS Genetic Testing (L36335)

### Alpha Listing:

#### Group 2 Codes:

C79.60	Secondary malignant neoplasm of unspecified ovary
C79.40	Secondary malignant neoplasm of unspecified part of nervous system
C78.30	Secondary malignant neoplasm of unspecified respiratory organ

C79.9	Secondary malignant neoplasm of unspecified site
C79.10	Secondary malignant neoplasm of unspecified urinary organs

#### Disclaimers:

This resource is intended to aid physicians and qualified office staff to identify diagnosis codes (ICD-10 codes) that support medical necessity.

The ICD-10 codes indicated in this guide are based on AMA guidelines and are common codes currently listed as medically supportive, and therefore covered, under Medicare's limited coverage policy.

Services must meet specific medical necessity requirements contained in any applicable statutes, regulations and manuals, as well as criteria defined by National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs). For every service billed, you must indicate the specific sign, symptom, or patient complaint that makes the service reasonable and necessary.

The accuracy and relevance of this information should be verified by reference to the current version of the Coding Manual of the American Medical Association (AMA) and by visiting the Centers for Medicare and Medicaid Services (CMS) Web site at [www.cms.hhs.gov/home/medicare.asp](http://www.cms.hhs.gov/home/medicare.asp). This information is not intended to suggest reimbursement or provide direction for coding and was obtained online at [www.cms.hhs.gov/home/medicare.asp](http://www.cms.hhs.gov/home/medicare.asp). Codes listed are effective as of February 1, 2019. To ensure the accurate and appropriate use of the information, it is recommended that the primary sources (i.e. CMS, MAC publications, notices, and advice) should be consulted periodically since information is often affected by ongoing developments.

All CPT codes provided above are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Codes listed are effective as of February 1, 2019

Noridian Healthcare Solutions, LLC is the Medicare Administrative Contractor (MAC) for Jurisdiction E and processes Medicare Part A and Part B claims for California, Nevada, Hawaii, Guam, American Samoa, and Northern Mariana Islands

Noridian Healthcare Solutions | Covers: California, Nevada, Hawaii



12701 Commonwealth Dr., Suite 9

Fort Myers, FL 33913

Phone: 866.776.5907 / Fax: 239.690.4327

[neogenomics.com](http://neogenomics.com)

© 2019 NeoGenomics Laboratories, Inc. All Rights Reserved.  
All other trademarks are the property of their respective owners.  
Rev. 021119